A key opinion leader discusses effective CV risk prevention measures, challenges to reducing adverse events, and effective patient education resources.
A key opinion leader discusses effective risk prevention measures and challenges to reducing adverse events. He also considers effective educational resources for self-care.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.